$6.17
4.58%
Nasdaq, Apr 21, 08:16 pm CET
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Kura Oncology, Inc. Stock price

$5.90
-1.39 19.07% 1M
-12.19 67.39% 6M
-2.81 32.26% YTD
-12.09 67.20% 1Y
-10.25 63.47% 3Y
-4.73 44.50% 5Y
-9.10 60.67% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.15 2.61%
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Key metrics

Market capitalization $476.59m
Enterprise Value $-234.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -4.35
P/S ratio (TTM) P/S ratio 8.85
P/B ratio (TTM) P/B ratio 1.12
Revenue (TTM) Revenue $53.88m
EBIT (operating result TTM) EBIT $-193.20m
Free Cash Flow (TTM) Free Cash Flow $133.85m
Cash position $727.40m
EPS (TTM) EPS $-2.02
P/E forward negative
P/S forward 3.59
EV/Sales forward negative
Short interest 11.00%
Show more

Is Kura Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Kura Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Kura Oncology, Inc. forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Kura Oncology, Inc. forecast:

Buy
87%
Hold
13%

Financial data from Kura Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
54 54
-
100%
- Direct Costs 0.85 0.85
0% 0%
2%
53 53
6,340% 6,340%
98%
- Selling and Administrative Expenses 75 75
54% 54%
140%
- Research and Development Expense 170 170
47% 47%
315%
-192 -192
17% 17%
-357%
- Depreciation and Amortization 0.85 0.85
0% 0%
2%
EBIT (Operating Income) EBIT -193 -193
17% 17%
-359%
Net Profit -174 -174
14% 14%
-323%

In millions USD.

Don't miss a Thing! We will send you all news about Kura Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kura Oncology, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – – Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation –
Neutral
GlobeNewsWire
17 days ago
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting...
Neutral
GlobeNewsWire
20 days ago
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a v...
More Kura Oncology, Inc. News

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Head office United States
CEO Troy Wilson
Employees 192
Founded 2014
Website www.kuraoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today